Beacon Select, best suited for small- to mid-sized biopharmaceutical companies, clinical research organizations (CROs), and contract development and manufacturing organizations (CDMOs), is intended to enable scientists to clone, culture, assay, and select top clones in a single run on a single platform.

The Beacon Select's optofluidic and NanoPen chamber technology and proprietary CLD applications are designed to meet new market segment customers' research and budgetary needs. The company contends that the system's high throughput cloning, screening, and selection of top-performing Chinese hamster ovary cell lines may help reduce overall bioprocessing costs, improve success probability, and shorten timelines.

Berkeley Lights will offer Beacon Select with various purchase options, including capital placement, lease, or reagent rental. The two-chip Beacon Select list price is approximately half the current four-chip Beacon system launched in 2017, which is geared for high-campaign usage from large biopharmaceutical and established CDMOs and CROs; it currently has approximately 130 systems installed globally.

"By the second half of 2023, we will also offer Beacon Quest, an optofluidic system specialized for academic research institutes and translational research centers," said Berkeley Lights CEO Siddhartha Kadia, PhD, in a statement.

Berkeley Lights highlights research, products at ESCAT 2022
Berkeley Lights is participating in the 27th Annual European Society for Animal Cell Technology (ESCAT), June 26-29 in Lisbon, in symposium sessions and...

Curia adopts Berkeley Lights platform to accelerate, expand antibody-based drug discovery
Contract research, development, and manufacturing organization Curia has adopted Berkeley Lights’ platform to accelerate and expand its antibody-based...

MImAbs acquires Beacon system of antibody therapeutics
MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to further the company's mission of generating and validating novel...

Berkeley Lights reports revenue spike in Q2
Berkeley Lights reported an 82% increase in revenue for the second quarter of 2021 compared to the same period a year ago.

Leveraging optofluidics to make therapeutic antibody discovery easier
The need for speed and accuracy in the development of therapeutic antibodies has prompted Berkeley Lights to upgrade its optofluidic tools to help customers...

Abveris expands antibody discovery offerings with second Beacon system
Abveris has starting using a second Berkeley Lights Beacon optofluidic system to enable expansion of its antibody discovery offerings.

Berkeley Lights offers new assays to aid cell line development
Berkeley Lights has launched Opto Assure, a series of assays that provides yield and product quality data during the early stages of cell line development.

Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher...